Every 8-K that HEPION PHARM INC PFD (CTRVP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTRVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTRVP filings page.
Hepion Pharmaceuticals, Inc. (HEPA) completed its acquisition of all issued and outstanding membership interests in Gravitas Life Sciences, LLC (GLS) from Gravitas Collective Corp., GLS’s sole member, on October 6, 2026. Consideration included $2,000,000 in cash and 25,000,000 common shares, with the shares stated as $2,250,000 divided by the Buyer Closing Stock Price. Issuance was capped at 19.99% of Hepion’s shares outstanding immediately following issuance, with any reduction settled in an equitable cash payment. Hepion also paid the seller $135,000. The shares are transfer-restricted until the earlier of six months after closing or registration for resale under an effective registration statement.
At closing, Hepion paid Canton Strategic Holdings $1,000,000 and GLS paid $125,000 from the cash consideration as prepayment of principal on the Canton Seller Note; Hepion became its sole maker, obligor and guarantor for remaining obligations. GLS develops GV104 for opioid-exposure prophylaxis and GV023, an oral infliximab formulation. GLS intends to file a GV104 NDA after CMC work; commercial-scale registration batches are intended to begin in 2027, and no dosing-window clinical study is in progress or scheduled. Disinterested directors approved the related-party transaction after directors Vincent LoPriore, Gary Stetz, Sireesh Appajosyula and Chase LoPriore disclosed interests and recused themselves; Hepion obtained a fairness opinion. Appajosyula was appointed CEO and Stetz CFO effective October 9, 2026.
Hepion Pharmaceuticals, Inc. (HEPA) amended its Certificate of Incorporation to increase the authorized number of common shares to 750,000,000. The amendment became effective upon filing on October 1, 2026.
Hepion Pharmaceuticals, Inc. (HEPA) entered into a financing transaction with Gravitas Capital LP on September 3, 2026, issuing a $500,000 secured convertible note and a warrant for 12,500,000 shares of common stock. The note bears 8% annual interest, payable in kind, and matures on September 3, 2027. It is convertible at the option of Gravitas at $0.04 per share any time on or after September 3, 2026, upon stockholder approval of an increase in authorized common shares. The warrant is exercisable at $0.06 per share from the same approval-based initial exercise date until September 3, 2031. The note is secured by all of the company’s assets under a separate security agreement, and the transaction documents include customary representations, covenants, conditions to closing, indemnification, and termination provisions.
Hepion Pharmaceuticals, Inc. (HEPA) entered into securities purchase agreements with certain accredited investors for a private placement of 8,000,000 shares of common stock and warrants to purchase 8,000,000 shares of common stock at an offering price of $0.05 per share, for gross proceeds of $400,000. The warrants are exercisable at an exercise price of $0.06 per share for a term of five years from issuance. The securities are being issued in an unregistered private offering relying on Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, and may not be offered or sold in the United States without registration or an applicable exemption. The agreements include customary representations, warranties, conditions to closing, indemnification obligations, and termination provisions.
Hepion Pharmaceuticals, Inc. (HEPA) announced that its Board of Directors appointed James Liddy as a director, effective August 19, 2026. The company states there are no arrangements or understandings with any other person regarding his selection and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
The report is signed on behalf of Hepion Pharmaceuticals by Gary Stetz, Interim Chief Executive Officer, dated August 20, 2026. No financial results or transactional developments are included in this disclosure; it is focused on corporate governance and board composition.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of equity and warrants. The company agreed to sell 61,100,000 shares of common stock at an offering price of $0.05 per share and issue warrants to purchase 61,100,000 additional shares, for gross proceeds of $3,055,000.
The warrants are exercisable at $0.06 per share for five years from the date of issuance. The agreements include customary representations, warranties, conditions to closing and indemnification obligations between Hepion and the investors. The offering closed on August 3, 2026.
The securities were offered in reliance on exemptions from Securities Act registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D and applicable state laws. As a result, the common stock and warrants issued may not be offered or sold in the United States without registration or an applicable exemption.
Hepion Pharmaceuticals, Inc. reported that its Board of Directors appointed Danina Fisher and Gary S. Stetz, II as directors, effective July 1, 2026. This expands the company’s board and adds new oversight at the corporate level.
The filing notes there are no arrangements or understandings with other persons related to their selection, and no family relationships among the new directors and other company figures, except that Gary S. Stetz, II is the son of Interim Chief Executive Officer Gary Stetz.
Hepion Pharmaceuticals reported the results of its 2026 annual stockholder meeting. Stockholders elected five directors – Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula, and Chase LoPriore – each receiving about 13.2 to 13.5 million votes in favor, with relatively few withheld and 4.8 million broker non-votes.
Stockholders also ratified Grassi & Co., CPAs, P.C. as independent auditors for the year ending December 31, 2026, with 18,128,998 votes for and limited opposition. In a key compensation item, they approved an amendment to the 2023 Omnibus Equity Incentive Plan to increase the shares issuable under the plan to 8,000,000 from 200,000. As of April 28, 2026, there were 29,119,476 common shares outstanding, including shares issuable upon conversion of Series A Preferred Stock.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons, effective immediately on March 16, 2026. The Board moved quickly to reconfigure leadership, naming Gary Stetz as interim CEO and a director the same day.
The Board also appointed Vincent LoPriore as Executive Chairman and added Sireesh Appajosyula and Chase LoPriore as directors. The company states there are no special arrangements behind these appointments and no family relationships between the new leaders and existing directors or executive officers.
Hepion Pharmaceuticals entered a material intellectual property license agreement with Cirna Diagnostics, adding a liver disease diagnostic asset to its portfolio. The company will pay an upfront $50,000, certain patent expenses, up to $2,350,000 in development milestones, up to $4,500,000 in sales milestones, and low single-digit royalties on net sales.
Hepion also highlighted a novel circulating tumor RNA biomarker assay for earlier diagnosis and surveillance of hepatocellular carcinoma in high-risk patients, reinforcing its strategic shift toward liquid biopsy-based cancer diagnostics under new leadership.
Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as Chief Executive Officer effective January 8, 2026, under a new employment agreement. She will receive an annual base salary of $350,000 and is eligible for an annual discretionary cash bonus targeted at 35% of base salary, based on goals set by the Board. Of the base salary, $50,000 is deferred and paid in cash only upon a qualifying equity financing of at least $3,000,000, certain termination events, or a change of control.
If a change of control occurs with an enterprise value of at least $5,000,000, Dr. Lbiati earns a bonus equal to 3.0% of that value. The agreement provides severance of six months of base compensation, benefits, and a pro-rated bonus if she is terminated without cause or resigns for good reason, along with full vesting of time-based equity awards. Additional protections apply in connection with death, disability, and specified change-of-control related terminations, including accelerated vesting and extended exercise periods for equity awards.